LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

Home・Stock List・ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc

Closed

SectorHealthcare

21.4 2.59

Buy Sell

Overview

Share price change

24h

Current

Min

20.61

Max

21.41

Key metrics
By Trading Economics
Income	-270M 3.6M
Sales	-16M 268M
P/E Sector Avg	9.738 49.888
EPS	0.02
Profit margin	1.357
Employees	796
EBITDA	-31M -4.6M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+50.23% upside

Dividends
By Dow Jones
Next Earnings	5 Aug 2026

Market Stats
By TradingEconomics
Market Cap	-114M 3.7B
Previous open	18.81
Previous close	21.4

News Sentiment

By Acuity

25%

75%

59 / 344 Healthcare

ACADIA Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

3 Jun 2026, 23:22 UTC

Earnings

Major Market Movers

Broadcom Shares Slide Despite Jump in 2Q Revenue on AI Chip Demand -- Update

3 Jun 2026, 23:09 UTC

Hot Stocks

Stocks to Watch: Broadcom, CrowdStrike, PVH, Petco

3 Jun 2026, 20:51 UTC

Earnings

Costco Reports 15% Sales Growth in May

3 Jun 2026, 20:43 UTC

Earnings

Broadcom 2Q Revenue Climbs on AI Chip Demand

3 Jun 2026, 23:48 UTC

Market Talk

Nikkei May Fall Amid Renewed Concerns About Iran Conflict -- Market Talk

3 Jun 2026, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 Jun 2026, 23:35 UTC

Market Talk

Oil Futures Fall on Possible Technical Correction -- Market Talk

3 Jun 2026, 23:15 UTC

Market Talk

Earnings

Five Below, Broadcom and Crowdstrike Fall Despite Solid Results -- Market Talk

3 Jun 2026, 22:08 UTC

Hot Stocks

After-Hours Stocks to Watch: CrowdStrike, Broadcom, Five Below -- WSJ

3 Jun 2026, 21:54 UTC

Market Talk

Correction to Oil Futures Rise on Concerns About U.S.-Iran Talks Article on June 1

3 Jun 2026, 21:18 UTC

Earnings

Broadcom's Non-AI Semiconductor Revenue Rose 6% in 2Q, CEO Says

3 Jun 2026, 21:15 UTC

Earnings

Broadcom CEO: Google Partnership Continues to Be 'Very Substantial'

3 Jun 2026, 21:13 UTC

Earnings

Broadcom CEO Expects AI Semiconductor Revenue Growth to Continue in Fiscal 2028

3 Jun 2026, 21:13 UTC

Earnings

Broadcom Continues to Expect AI Semiconductor Revenue of More Than $100B in 2027, CEO Says

3 Jun 2026, 21:12 UTC

Earnings

Broadcom Expects AI Semiconductor Revenue of $56B This Year, CEO Says

3 Jun 2026, 21:09 UTC

Earnings

Broadcom CEO: Networking Made Up Almost 40% of AI Revenue in 2Q

3 Jun 2026, 21:03 UTC

Earnings

Broadcom Stock Falls After Earnings. Here's Why. -- Barrons.com

3 Jun 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3 Jun 2026, 20:43 UTC

Earnings

CrowdStrike Stock Falls Despite Earnings Beat -- Barrons.com

3 Jun 2026, 20:39 UTC

Acquisitions, Mergers, Takeovers

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 4th Update

3 Jun 2026, 20:37 UTC

Acquisitions, Mergers, Takeovers

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 3rd Update

3 Jun 2026, 20:35 UTC

Earnings

Broadcom Stock Falls Despite Record Results -- Barrons.com

3 Jun 2026, 20:21 UTC

Acquisitions, Mergers, Takeovers

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 2nd Update

3 Jun 2026, 20:17 UTC

Earnings

Broadcom 2Q Semiconductor Solutions Revenue $15B >AVGO

3 Jun 2026, 20:17 UTC

Earnings

Broadcom Sees 3Q Semiconductor Revenue From AI $16B >AVGO

3 Jun 2026, 20:15 UTC

Acquisitions, Mergers, Takeovers

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- Update

3 Jun 2026, 20:15 UTC

Earnings

Broadcom 2Q Adj EPS $2.44 >AVGO

3 Jun 2026, 20:15 UTC

Earnings

Broadcom 2Q EPS $1.91 >AVGO

3 Jun 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

3 Jun 2026, 20:15 UTC

Earnings

Broadcom 2Q Rev $22.19B >AVGO

Peer Comparison

Price change

ACADIA Pharmaceuticals Inc Forecast

Price Target

By TipRanks

50.23% upside

12 Months Forecast

Average 32.33 USD 50.23%

High 38 USD

Low 23 USD

Based on 14 Wall Street analysts offering 12 month price targets forACADIA Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

14 ratings

Buy

Hold

Sell

Based on 14 analysts giving stock ratings to ACADIA Pharmaceuticals Inc - Dist in the past 3 months.

Sentiment

By Acuity

59 / 344 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.